Mr.He-JiunJiang Taiwan

Mr.He-JiunJiang
Dr. He-Jiun (Donald) Jiang, MD, MSc, is an endocrinologist who serves as Director of the Division of Endocrinology and Metabolism at E-Da Dachang Hospital in Kaohsiung, Taiwan, and as Deputy Secretary-General of the Endocrine Society of the Republic of China (Taiwan) since 2022. He earned his MD (2007) and MSc (2018) at Kaohsiung Medical University and previously served at Kaohsiung Medical University Hospital. His clinical and research interests focus on differentiated thyroid carcinoma, including molecular profiling, ultrasound-guided diagnosis, lymph-node metastasis, and thyroid radiofrequency ablation. He led a 2021 real-world study of low-dose lenvatinib for radioiodine-refractory differentiated thyroid carcinoma, highlighting experience from Taiwan. He also authored a 2020 article on thyroglobulin measurement via ultrasound-guided fine-needle aspiration to diagnose lymph-node metastasis, which is cited in the 2025 American Thyroid Association guideline for differentiated thyroid carcinoma. At AOCE, Dr. Jiang will share Taiwan’s experience with redifferentiation therapy, emphasizing patient selection, imaging workflows, and outcomes within multidisciplinary care.

22 MARCH

Time Session
11:00
12:30
[Symposium] Thyroid (5)
Novel Treatment and Diagnostic Approaches for Thyroid Cancer in Post-NGS Era
  • Advances in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Multikinase Inhibitors and Beyond – An Asian Perspective
    Won Gu KimKorea (Republic of) Speaker Advances in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Multikinase Inhibitors and Beyond – An Asian Perspective
  • The Genetic Landscape of Thyroid Cancer
    Young Joo ParkKorea (Republic of) Speaker Translating the Genetic Landscape of Thyroid Cancer to Precision Diagnosis and TherapyThyroid cancer is characterized by a relatively low mutational burden compared with other solid tumors, with recurrent alterations mainly involving BRAF, RAS, and various fusion genes. Several novel driver candidates have also been identified through next-generation sequencing studies. The frequency and pattern of these genomic alterations differ across thyroid cancer subtypes and are often associated with distinct histopathological phenotypes, providing valuable clues for differential diagnosis. Moreover, molecular subtypes defined by driver mutations are closely linked to tumor biology and clinical behavior, allowing more accurate prediction of disease aggressiveness and prognosis. Most differentiated thyroid cancers (DTCs) harbor a single dominant driver alteration; however, acquisition of additional mutations such as TERT promoter, tumor suppressor genes, or PI3K–AKT pathway alterations may lead to dedifferentiation and progression to aggressive or metastatic disease. Advances in our understanding of these genetic alterations have refined the pathological classification of thyroid cancer and enabled improved prognostication, treatment selection, and follow-up strategies. Importantly, the identification of actionable genetic alterations—including RET and NTRK fusions, as well as BRAF mutations—has revolutionized therapeutic approaches. Targeted agents such as selpercatinib, pralsetinib, larotrectinib, and entrectinib demonstrate substantial clinical efficacy with fewer adverse events than multikinase inhibitors, while dabrafenib plus trametinib has shown marked benefit in anaplastic thyroid cancer. With multiple targetable mutations being uncovered, incorporating comprehensive genomic testing into the diagnostic workflow is essential to guide precision therapy for patients with thyroid cancer.
  • Redifferentiation Strategies in Refractory Thyroid Cancer: First Insights from Taiwan
    He-Jiun JiangTaiwan Speaker Redifferentiation Strategies in Refractory Thyroid Cancer: First Insights from Taiwan
201BC